NASDAQ : ADMA
ADMA Biologics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 11.41 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.56B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.51B |
| Enterprise Value | 2.57B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 223.98M |
| Shares Outstanding | 223.98M |
| Shares Change (YoY) | +1.15% |
| Shares Change (QoQ) | -4.01% |
| Owned by Insiders (%) | 1.89% |
| Owned by Institutions (%) | 92.18% |
| Float | 219.66M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 15.98 |
| Forward PE | 13.60 |
| PS Ratio | 4.92 |
| Forward PS | 4.33 |
| PB Ratio | 6.30 |
| P/TBV Ratio | 6.24 |
| P/FCF Ratio | 21.64 |
| P/OCF Ratio | 18.43 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 15.32 |
| EV / Sales | 5.05 |
| EV / EBITDA | 11.54 |
| EV / EBIT | 11.95 |
| EV / FCF | 22.22 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.97 |
| Quick Ratio | 3.62 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 0.90 |
| Debt / FCF | 1.75 |
| Interest Coverage | 24.53 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 41.90% |
| Return on Assets (ROA) | 21.78% |
| Return on Invested Capital (ROIC) | 36.24% |
| Return on Capital Employed (ROCE) | 35.58% |
| Weighted Average Cost of Capital (WACC) | 7.72% |
| Revenue Per Employee | $791,770 |
| Profits Per Employee | $261,141 |
| Employee Count | 647 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 0.84 |
Taxes
| Measure | Value |
|---|
| Income Tax | 47.52M |
| Effective Tax Rate | 21.95% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -27.49% |
| 50-Day Moving Average | 10.03 |
| 200-Day Moving Average | 10.93 |
| Relative Strength Index (RSI) | 60.13 |
| Average Volume (20 Days) | 2,616,049 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.53M |
| Short Previous Month | 20.60M |
| Short % of Shares Out | 8.72% |
| Short % of Float | 8.89% |
| Short Ratio (days to cover) | 5.82 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 512.28M |
| Gross Profit | 331.47M |
| Operating Income | 216.50M |
| Pretax Income | 216.48M |
| Net Income | 168.96M |
| EBITDA | 224.19M |
| EBIT | 216.50M |
| Earnings Per Share (EPS) | $0.70 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 136.02M |
| Total Debt | 203.84M |
| Net Cash | -67.82M |
| Net Cash Per Share | -$0.30 |
| Equity (Book Value) | 408.21M |
| Book Value Per Share | 1.81 |
| Working Capital | 452.45M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 136.72M |
| Capital Expenditures | -20.25M |
| Depreciation & Amortization | 7.69M |
| Net Borrowing | 123.12M |
| Free Cash Flow | 116.47M |
| FCF Per Share | $0.52 |
Margins
| Measure | Value |
|---|
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Pretax Margin | 42.26% |
| Profit Margin | 32.98% |
| EBITDA Margin | 43.76% |
| EBIT Margin | 42.26% |
| FCF Margin | 22.74% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.15% |
| Shareholder Yield | -1.15% |
| Earnings Yield | 6.26% |
| FCF Yield | 4.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.00 |
| Price Target Difference | 51.92% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 12.65% |
| EPS Growth Forecast (3Y) | 22.26% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 10.04 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |